Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001013:Aorta, Thoracic / Q000473:pathology; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000473:pathology; D002784:Cholesterol / Q000008:administration & dosage / Q000097:blood; D003348:Cortisone / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004195:Disease Models, Animal; D005438:Fludrocortisone / Q000494:pharmacology; D005439:Flufenamic Acid / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology*; D006854:Hydrocortisone / Q000494:pharmacology; D008297:Male; D008528:Mefenamic Acid / Q000494:pharmacology; D008775:Methylprednisolone / Q000494:pharmacology; D010113:Oxyphenbutazone / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology; D011241:Prednisone / Q000494:pharmacology; D011817:Rabbits; D013997:Time Factors; D014221:Triamcinolone / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D014221:Triamcinolone; D008528:Mefenamic Acid; D005439:Flufenamic Acid; D003907:Dexamethasone; D002784:Cholesterol; D010653:Phenylbutazone; D010113:Oxyphenbutazone; D005438:Fludrocortisone; D003348:Cortisone; D011241:Prednisone; D006854:Hydrocortisone; D008775:Methylprednisolone